BPC-157 Dosage

There is no established, validated or approved human dose for BPC-157. Unlike the GLP-1 compounds, BPC-157 has essentially no human clinical trials behind it — no completed dose-ranging study, no efficacy trial, and no approved dosing instruction of any kind. The numbers people quote do not come from human research; they are drawn from animal studies — overwhelmingly rat experiments from a single research group — and from research-community convention that has grown up around those figures. This page explains what that evidence base actually is, so you can read any "BPC-157 dosage" figure for what it is.

That framing matters, because BPC-157 is discussed online as if it had a settled protocol. It does not. Everything below is written for laboratory and research reference only, and is separate from the shop, which exists only to specify and supply the research compound; for stocked formats and strengths, start at the BPC-157 product page. None of this is medical, prescribing or dosing advice.

What the evidence base actually is

BPC-157 (a stable gastric pentadecapeptide, a 15-amino-acid fragment) has been studied almost entirely in animals. The great majority of the literature comes from a Croatian laboratory associated with Predrag Sikiric and collaborators, who over several decades reported effects in rat and mouse models of tendon, muscle, gut, nerve and vascular injury. That body of work is large, but it is preclinical: it tells you what happened in rodents under experimental conditions, not what a safe or effective amount is in a person.

The human record is extremely thin. As of 2025, narrative and systematic reviews could identify only a handful of small pilot studies in people — for example an uncontrolled intra-articular knee-pain series, a small interstitial-cystitis series, and an early intravenous safety study in a couple of healthy adults. None was a dose-ranging efficacy trial, and reviewers concluded the compound should not be recommended for clinical use until rigorous trials are done. The animal literature is where the dosing figures originate, and the human literature is nowhere near strong enough to validate them.

The evidence basis at a glance

The table contrasts where the figures come from. Neither the animal doses nor the community ranges are a validated human protocol, and there is no approved human dose. The animal figures are per-kilogram rodent doses that do not convert to a person; the community figures have no trial basis at all.

Where the figure comes from	What was reported / what circulates	What it is — and is not
Animal (preclinical) studies — chiefly rat models from Sikiric et al.	Commonly around 10 µg/kg and 10 ng/kg per dose, given intraperitoneally, orally in drinking water, or applied topically, usually once daily across an injury model.	Rodent experimental doses. They demonstrate biological activity in animals; they do not translate into a human milligram or microgram dose.
Commonly-cited research / community ranges	Figures on the order of a few hundred micrograms per day are widely repeated in research-community discussion.	Convention, not evidence. No clinical trial supports these numbers and no dose is approved.

Why there is no validated human dose

A validated dose is the output of a process BPC-157 has never been through: dose-finding studies in people that measure how much produces a defined effect, at what exposure and safety margin, reproduced by independent groups. That process has barely begun, and the preclinical data cannot substitute for it.

• Animal doses do not scale directly to humans. A µg/kg dose in a rat is not the same as the equivalent in a person; allometric differences, route and metabolism all intervene. Converting a rodent figure into a human number is an assumption, not a measurement.
• The human safety window is unknown. Long-term human safety data simply do not exist, and the compound's mechanisms — including effects on blood-vessel growth (angiogenesis) — are exactly the kind that need careful human study before any dose can be called safe.
• Most evidence is from one source. A literature dominated by a single research group, and largely unreplicated in humans, is a weak foundation for a dosing recommendation.

So when a figure is presented as "the BPC-157 dose", it is research-community convention on top of animal data — not a tested human protocol.

Reconstituting a lyophilised BPC-157 vial

BPC-157 is usually supplied as a lyophilised (freeze-dried) powder, not a ready-to-use liquid, so it must be reconstituted with bacteriostatic water before any volume can be drawn. The amount of water you add sets the concentration, and the concentration decides how many units on an insulin syringe correspond to a given amount of peptide: add more water and each unit carries less; add less and each carries more. For example, adding 2 mL of bacteriostatic water to a 10 mg vial produces a 5 mg/mL solution — arithmetic about concentration, not a recommended amount to use.

Do the maths before you touch the vial, and remember there is no validated target to aim at. Our peptide reconstitution calculator is the companion to this guide: enter the vial strength, the water volume and a figure you want to model, and it returns the draw volume on a standard insulin syringe. It computes concentration and draw volume only; it does not tell you what amount is appropriate, because none has been established. The same handling applies to related research peptides such as TB-500, often co-studied with BPC-157 in the animal literature. For the general mechanics of preparing an injectable research peptide, see peptide injections.

Storage

BPC-157 is a peptide and is temperature- and light-sensitive. As a general handling matter, the lyophilised powder is comparatively stable and is best kept refrigerated at about 2–8 °C, protected from light and away from freezing; unopened dry vials tolerate short periods at room temperature far better than a reconstituted solution does. Once reconstituted, the solution is kept refrigerated at 2–8 °C, protected from light, and used within a limited window rather than stored indefinitely. Always defer to the certificate of analysis and any handling notes supplied with your specific batch, which take precedence over general guidance.

Cautions

Because the human evidence is so limited, the honest position is uncertainty rather than reassurance:

• Long-term human safety is unknown. There is no body of human safety data, so claims that BPC-157 is "well tolerated" rest on animal work and anecdote, not controlled human study.
• No effective dose has been demonstrated in people. Any figure you adopt is unvalidated by definition.
• Suitability cannot be judged from a page. Interactions and existing conditions are what a qualified professional weighs and a web page cannot.

Before making any decision involving BPC-157 or any research peptide, consult a registered healthcare professional. For the broader safety picture across peptides, see are peptides safe?

Research-use and medical disclaimer

Everything on this page is provided strictly for laboratory and research reference. It is not medical advice, not prescribing advice, and not a human dosing protocol. BPC-157 has no validated human protocol and no approved dose; the figures above describe what animal studies administered and what conventions circulate. They are not instructions and not recommendations to use any amount. BeSkinny supplies BPC-157 as a research compound only, and nothing here replaces a conversation with a registered healthcare professional.

Frequently asked questions

What is the BPC-157 dose?

There is no established human dose. The figures that circulate — most often on the order of a few hundred micrograms per day — are research-community convention built on animal studies, not human trials. Animal experiments commonly used doses around 10 µg/kg or 10 ng/kg in rats, which do not convert directly to a person. Treat any quoted "dose" as unvalidated, and take questions about amounts to a professional.

Is there an approved human dose for BPC-157?

No. BPC-157 has essentially no completed human clinical trials, no dose-ranging study and no approved dosing instruction. The only human reports are a few small, mostly uncontrolled pilot studies that cannot establish a safe or effective dose. Anyone presenting a figure as an official or validated BPC-157 dose is mistaken.

How do you reconstitute BPC-157?

A lyophilised vial is a freeze-dried powder that must be dissolved in bacteriostatic water before any volume can be drawn. The water volume you add sets the concentration and therefore the syringe units per microgram — for example, 2 mL added to a 10 mg vial gives 5 mg/mL. Work the numbers out first with the peptide reconstitution calculator. It handles the arithmetic only; it does not define an appropriate amount, because none has been validated.

Oral or injectable BPC-157 — which is used?

Both routes appear in the literature. In the rat studies, BPC-157 was given by injection (intraperitoneally), orally in drinking water, and topically; some human pilot reports used injection or intravenous routes. Because none of this establishes a human protocol, the choice of route is a matter for a qualified professional — only the research context is offered here.

How long is BPC-157 used for?

There is no validated duration, because there is no validated protocol. Animal studies ran from a single dose to weeks or months depending on the injury model, and research-community discussion repeats various "cycle" lengths, but none has a human trial behind it. Any real-world decision belongs with a registered healthcare professional, not a web page.

Sources

Note the central point below: there are no completed human randomised controlled trials of BPC-157, so all dosing figures derive from preclinical (animal) work and research convention.

• Narrative review documenting the sparse human evidence and preclinical basis: Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. PMC, 2025. pmc.ncbi.nlm.nih.gov
• Jóźwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals. 2025;18(2):185. pmc.ncbi.nlm.nih.gov
• Representative Sikiric et al. preclinical rat study documenting 10 µg/kg and 10 ng/kg dosing by intraperitoneal and per-oral routes: Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats. PubMed
• Preclinical safety evaluation of body protective compound-157 (animal toxicology context). ScienceDirect, 2020. sciencedirect.com
• Secondary reporting on the scant human evidence and regulatory questions: BPC-157 — big claims and scant evidence. STAT, 2026. statnews.com